Roche Holding AG

Roche Holding AG, headquartered in Switzerland and operating within the Pharmaceutical Preparation Manufacturing industry, has reported significant greenhouse gas emissions. For the reporting year 2025, total emissions were approximately 4.2 billion kg CO2e. This figure comprises Scope 1 emissions of about 211.9 million kg CO2e, Scope 2 emissions (market-based) of approximately 8.5 million kg CO2e, and substantial Scope 3 emissions totalling around 3.9 billion kg CO2e. Purchased goods and services represent the largest contributor to their Scope 3 emissions, amounting to approximately 3.8 billion kg CO2e.

In 2024, Roche's total emissions were approximately 4.7 billion kg CO2e, with Scope 1 at about 245.8 million kg CO2e, Scope 2 (market-based) at approximately 69.2 million kg CO2e, and Scope 3 emissions totalling around 4.3 billion kg CO2e. The category of purchased goods and services was again the largest component of Scope 3, with approximately 3.9 billion kg CO2e.

Looking at 2023, total emissions were approximately 7.0 billion kg CO2e, including Scope 1 emissions of 240.3 million kg CO2e and Scope 2 emissions of 98.5 million kg CO2e. Scope 3 emissions for 2023 were approximately 5.9 billion kg CO2e, with purchased goods and services being the most significant contributor at around 4.5 billion kg CO2e.

Roche has established ambitious climate commitments, including a long-term goal to achieve net-zero emissions across its entire value chain by 2045. This commitment is further supported by Science Based Targets initiative (SBTi) approved goals. Specifically, Roche aims to reduce absolute Scope 1 and 2 greenhouse gas emissions by 70% by 2029, from a 2022 base year. Additionally, there is a commitment to reduce absolute Scope 3 GHG emissions from specific categories, including fuel- and energy-related activities, waste generated in operations, and business travel, by 22.5% within the same timeframe. Further Scope 3 reductions of 22.5% are targeted for emissions from the use and end-of-life treatment of sold products. Looking further ahead, Roche commits to reducing absolute Scope 1 and 2 GHG emissions by 90% by 2045, with a corresponding 90% reduction in absolute Scope 3 GHG emissions over the same period. They also aim to have 70% of their suppliers, by emissions covering purchased goods and services, capital goods, and upstream transportation and distribution, demonstrate science-based targets by 2029.